Objective: The aim of the present study was to know if a global assessment of Parkinson’s disease (PD) using a new proposed index correlated with changes in quality of life (QoL) and autonomy for activities of daily living (AADL).

Background: PD is a complex neurodegenerative disorder characterized by a combination of motor symptoms, non-motor symptoms, and cognitive impairment. All of these progress over time and impact QoL and AADL, so the patient assessment must be comprehensive.

Method: Using data of PD patients from specific scales (UPDRS [Unified Parkinson´s Disease Rating Scale]; NMSS [Non-Motor Symptoms Scale]; BDI-II [Beck Depression Inventory II]; FOGQ [Freezing of Gait Questionnaire]; PD-CRS [Parkinson´s Disease Cognitive Rating Scale]) from the COPPADIS cohort (references 1 and 2), firstly, we applied a score at baseline (V0) and at 5-year follow-up (V5) defined as Global Parkinson´s Symptoms Score (GPSS = [UPDRS-III-OFF + UPDRS-IV + NMSS + BDI-II + FOGQ / PD-CRS] x 100). Secondly, we applied an index to evaluate disease progression at V5, defined as the Global Parkinson´s Symptoms Index (GPSI = [GPSS at V5 – GPSS at V0 / GPSS at V5] x 100). QoL and AADL were assessed with the PDQ-39SI, PQ-10 and EUROHIS-QOL8, and the Schwab and England scale (ADSL), respectively. Correlation coefficients and non-parametric statistical tests were applied.

Results: A strong correlation was observed between the PDQ-39SI and the GPSS at V0 (r=0.720; N=606; p<0.0001) and at V5 (r=0.780; N=345; p<0.0001). Moderate significance were observed for the rest of the correlations at V0 and at V5 (Table 1). The GPSS increased significantly from 80.1 ± 54.7 at V0 to 146.3 ± 134.5 at V5 (N=317; p<0.0001). At V5, 56 patients out of 317 patients (17.7%) had a negative GPSI (Figure 1), with no impairment in QoL (PDQ-39SI, PQ-10, EUROHIS-QoL) compared with the group with a positive GPSI and with a significantly lesser impairment in AADL (Figure 2). Moderate correlations were found between the GPSI and the change from V0 to V5 in the PDQ-39SI, EUROHIS-QOL8, and the ADSL (Table 1).

Conclusion: GPSS and GPSI correlated with QoL and AADL, suggesting that they could be useful to monitor the progression of PD.

Table

Figure 1

Figure 2

References: 1. Santos-García D, Mir P, Cubo E, Vela L, Rodríguez-Oroz MC, Martí MJ, Arbelo JM, Infante J, Kulisevsky J, Martínez-Martín P; COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global–clinical evaluations, serum biomarkers, genetic studies and neuroimaging–prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression. BMC Neurol. 2016 Feb 25;16:26. doi: 10.1186/s12883-016-0548-9.

2. Santos García D, Jesús S, Aguilar M, Planellas LL, García Caldentey J, Caballol N, Legarda I, Hernández Vara J, Cabo I, López Manzanares L, González Aramburu I, Ávila Rivera MA, Catalán MJ, López Díaz L, Puente V, García Moreno JM, Borrué C, Solano Vila B, Álvarez Sauco M, Vela L, Escalante S, Cubo E, Carrillo Padilla F, Martínez Castrillo JC, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Kulisevsky J, Menéndez González M, Seijo M, Rúiz Martínez J, Valero C, Kurtis M, de Fábregues-Boixar O, González Ardura J, Prieto Jurczynska C, Martinez-Martin P, Mir P; COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015): an ongoing global Parkinson’s disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation. Eur J Neurol. 2019 Nov;26(11):1399-1407. doi: 10.1111/ene.14008.

« Back to 2026 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/global-parkinsons-symptoms-index-correlates-with-changes-in-quality-of-life-and-autonomy-for-activities-of-daily-living/